Finance Manager

Oxford BioMedica (UK) Limited; Oxford; On-site; GBP 70,000 - 95,000; Full time

Benefits offered by this job

Competitive total rewards

Wellbeing programs

Career development opportunities

Supportive, inclusive culture

Job summary

Oxford Biomedica seeks a Financial Manager to join UK Finance Control. You will own the month-end process and controls, lead accounting for UK Cost of Sales, Inventory, Fixed Assets, and Lease Accounting, and drive robust financial reporting.

You will develop the team, strengthen controls, and act as a finance partner across the business. ERP system expertise and strong Excel skills are essential to ensure accurate, timely reporting.

Qualifications

• Qualified accountant with ACA/ACCA/CIMA and strong technical accounting experience.
• Experience leading UK cost of sales, inventory, fixed assets and lease accounting.
• Proven ability to manage and develop finance teams.

Responsibilities

• Own the month-end process and financial reporting across assigned areas.
• Lead accounting for UK Cost of Sales, Inventory, Fixed Assets, and Lease Accounting.
• Develop and coach direct reports to maintain a high-performing team.
• Strengthen financial controls and improve reporting accuracy and processes.
• Partner with stakeholders and provide financial guidance across the business.
• Act as ERP system subject matter expert and drive system improvements.
• Deliver insightful analysis and commentary on performance, trends, and variances.
• Support group reporting and contribute to statutory accounts and year-end audits.

Skills

Advanced Excel

ERP systems

Stakeholder management

Leadership / people management

Financial analysis

Education

Qualified accountant (ACA/ACCA/CIMA)

Tools

ERP systems

MS Excel

Job description

• Take ownership of the month-end process, ensuring accurate, timely, and compliant financial reporting across your areas of responsibility.
• Lead the accounting and reporting for UK Cost of Sales, Inventory, Fixed Assets, and Lease Accounting.
• Lead, develop and support direct reports, providing clear objectives, regular coaching and performance feedback to ensure a high-performing and engaged team.
• Maintain and strengthen financial controls, identifying opportunities to improve processes, mitigate risk, and enhance reporting accuracy.
• Act as a trusted finance partner to stakeholders across the business, building strong relationships and providing financial guidance and support.
• Serve as a subject matter expert for the ERP system within Finance, supporting users and driving system improvements.
• Deliver insightful financial analysis and commentary, helping business leaders understand performance, trends, and variances.
• Support Group reporting requirements and contribute to the preparation of statutory accounts and year-end audits.

• ACA, ACCA or CIMA qualification
• Proven experience as a qualified accountant working within finance or an accounting practice with strong technical experience.
• Good understanding of financial reporting and processes in a business environment
• Experience working with ERP systems and complex financial data.
• Good Microsoft Office skills with advanced skills in MS Excel.
• Strong communication and relationship-building skills, with the ability to work effectively across multiple functions.

OXB is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Job description

Join Us in Changing Lives

At OXB, our people are at the heart of everything we do. Were on a mission to enable life-changing therapies to reach patients around the worldand were looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful.

We are currently recruiting for a Financial Manager to join our UK Finance Control Team. In this role, you will take ownership for the month-end process and controls, playing a key part in advancing our mission and making a real difference., OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXBs world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US.

Why Join Us?

• Competitive total reward packages
• Wellbeing programs that support your mental and physical health
• Career development opportunities to help you grow and thrive
• Supportive, inclusive, and collaborative culture
• State-of-the-art labs and manufacturing facilities
• A company that lives its values:Responsible, Responsive, Resilient, Respect

Ready to Make a Difference?

The closing date for applications is Tuesday 17th November 2026.

We want you to feel inspired every day. At OXB, were future-focused and growing fast. We succeed togetherthrough passion, commitment, and teamwork.

Please note: Our vacancies are typically advertised for a minimum of 10 working days. Once a vacancy closes, it may take a few days for us to provide an update while our Talent Acquisition team and Hiring managers review all applications.

Every application is reviewed manually by our recruitment team and hiring managers. We do not use AI to screen CVs or make shortlisting decisions.

We offer

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.